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Abstract
In Alzheimer’s disease (AD) and other tauopathies, the microtubule-associated protein tau can undergo aberrant
hyperphosphorylation potentially leading to the development of neurofibrillary pathology. Anesthetics have been
previously shown to induce tau hyperphosphorylation through a mechanism involving hypothermia-induced inhibition of
protein phosphatase 2A (PP2A) activity. However, the effects of propofol, a common clinically used intravenous anesthetic,
on tau phosphorylation under normothermic conditions are unknown. We investigated the effects of a general anesthetic
dose of propofol on levels of phosphorylated tau in the mouse hippocampus and cortex under normothermic conditions.
Thirty min following the administration of propofol 250 mg/kg i.p., significant increases in tau phosphorylation were
observed at the AT8, CP13, and PHF-1 phosphoepitopes in the hippocampus, as well as at AT8, PHF-1, MC6, pS262, and
pS422 epitopes in the cortex. However, we did not detect somatodendritic relocalization of tau. In both brain regions, tau
hyperphosphorylation persisted at the AT8 epitope 2 h following propofol, although the sedative effects of the drug were
no longer evident at this time point. By 6 h following propofol, levels of phosphorylated tau at AT8 returned to control
levels. An initial decrease in the activity and expression of PP2A were observed, suggesting that PP2A inhibition is at least
partly responsible for the hyperphosphorylation of tau at multiple sites following 30 min of propofol exposure. We also
examined tau phosphorylation in SH-SY5Y cells transfected to overexpress human tau. A 1 h exposure to a clinically relevant
concentration of propofol in vitro was also associated with tau hyperphosphorylation. These findings suggest that propofol
increases tau phosphorylation both in vivo and in vitro under normothermic conditions, and further studies are warranted to
determine the impact of this anesthetic on the acceleration of neurofibrillary pathology.
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Introduction
Alzheimer’s disease is the leading cause of dementia and as of 2006,
the worldwide prevalence of the disease was 26.6 million [1].
Alzheimer’s disease is histopathologically characterized by the
presence of extracellular senile plaques comprised primarily of
aggregated b-amyloid peptides [2], as well as intraneuronal neurofi-
brillary tangles (NFTs) that are composed of insoluble aggregates of
hyperphosphorylated tau protein [3,4]. Tau protein is a microtubule-
associated protein abundantly found in neuronal axons. In AD and
other neurodegenerative tauopathies, tau can be abnormally hyper-
phosphorylated, leading to its self-assembly into straight or paired
helical filaments, the major components of NFTs [5,6].
The etiology of Alzheimer’s disease is probably multifactorial,
and there is growing interest in the potential relationship between
anesthesia and the onset and progression of Alzheimer’s disease
[7,8,9,10]. Many pre-clinical studies have demonstrated that
anesthetics can enhance b-amyloid toxicity and aggregation both
in vitro and in vivo [11,12,13,14]. In terms of tau protein, we
demonstrated that both inhalational and intravenous anesthetics
produce tau hyperphosphorylation through a mechanism involv-
ing the inhibition of protein phosphatase 2A (PP2A) activity by
anesthesia-induced hypothermia [15]. We have also shown that
anesthesia can affect tau functional dynamics; in a transgenic
mouse model expressing all 6 isoforms of normal human tau,
pentobarbital-induced hypothermia hyperphosphorylates tau, thus
impairing its ability to bind and assemble microtubules (MTs) [16].
Moreover, in a transgenic mouse model of tau pathology, we
observed that isoflurane-induced hypothermia accelerates neuro-
fibrillary pathology [17].
It has been recently demonstrated that anesthetics can also
produce tau hyperphosphorylation in the absence of hypothermia
[18]. However, this study focused on the effects of ether and sodium
pentobarbital, anesthetics that are rarely used in current clinical
anesthesia practice. Propofol (2,6 diisopropylphenol) is an intrave-
nous sedative-hypnotic, commonly used as an anesthetic for
procedures requiring general anesthesia and conscious sedation as
well as for prolonged sedation in intensive care units [19]. Given the
recent findings by Run et al. [18], we investigated whether a general
anesthetic dose of propofol would increase the phosphorylation of
tau in the absence of hypothermia. Hence, the purpose of this study
was to examine the direct impact of propofol on tau phosphory-
lation under normothermic conditions in vivo, as this would more
closely mimic clinical anesthetic exposure. We observed that
propofol leads to tau hyperphosphorylation under normothermic
conditions both in mice and in human neuroblastoma cells.
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Propofol Increases Tau Phosphorylation Under
Hypothermic and Normothermic Conditions in the
Mouse Hippocampus
We first wanted to confirm that propofol would induce
hypothermia-mediated tau hyperphosphorylation, as it has not
been reported previously. Thirty min following propofol admin-
istration, significant hypothermia occurred in the group of mice
whose temperature was not controlled during anesthesia (Hypo-
thermia, n=5). The mouse rectal temperature decreased to
30.961.0uC in the hypothermia group versus 37.560.4 and
37.560.6uC in the control (n=4) and temperature controlled
(Normothermia, n=5) groups, respectively (P,0.001 vs. control).
As expected, given that anesthesia-induced hypothermia inhibits
the activity of PP2A [15], propofol-induced hypothermia pro-
duced a significant increase in hippocampal tau phosphorylation
at the AT8 (11356325%), PHF-1 (265628%), and CP13
(525663%) phosphoepitopes (Fig.1A1, A2, A3), when compared
to the control group, and there was a slight increase (11262%) in
total tau in the hypothermic group (Fig. 1A4). Nevertheless,
significant tau hyperphosphorylation at AT8 (161636%), PHF-1
(23165 1%), and CP13 (200625%) was also observed in the
hippocampal tissue of the normothermic group (Fig.1B1, B2, B3).
Overall, our data indicate propofol can induce tau hyperpho-
sphorylation by inducing hypothermia, but can also do so in the
absence of hypothermia, albeit to a lesser extent.
Hyperphosphorylated Tau does not Relocalize in the
Somato-Dendritic Compartment
In the normal adult brain, tau is an axonal protein, with a
typical pattern of staining in the neuropil and axonal tracks, but
not in the somatodendritic compartment. In AD, tau-positive
dystrophic axons are widespread, and the earliest detectable
hyperphosphorylated tau is preferentially localized in neurites of
vulnerable neurons before extending to the soma [20]. We thus
examined the gross anatomical pattern of tau phosphorylation, to
see whether propofol-induced tau hyperphosphorylation would
induce a somadendritic relocalization of tau, one of the early signs
of tau pathology. There was a robust hyperphosphorylation of tau
at the AT8 epitope 30 min after propofol injection under
hypothermic conditions (Fig. 2B), and to a much lesser extent
30 min after propofol treatment under normothermic conditions
(Fig. 2C). However, there was no observable change in total or
phospho-tau cellular localization, as revealed by AT8, Total Tau,
and DAPI staining patterns. These results confirm our Western
blot data, which revealed large changes in tau phosphorylation at
the AT8 epitope (Fig. 1A) in response to propofol-induced
hypothermia, but smaller changes in phosphorylation when the
animals were kept normothermic (Fig. 1B), and reveal that short
Figure 1. Tau phosphorylation in mouse hippocampal tissue 30 min following the administration of propofol under hypothermic
(A) or normothermic (B) conditions. Hippocampal protein extracts were separated by SDS-PAGE and levels of tau phosphorylation were
determined using antibodies directed at the AT8 (Ser
202/Thr
205;A1,B1), CP13 (Ser
202;A2,B2), and PHF-1 (Ser
396/Ser
404;A3,B3) phosphoepitopes, or total
tau (A4, B4). Relative immunoreactive band intensities are expressed as a percent of control (Ctl; intralipid) and are displayed for each
phosphoepitope and total tau. For each condition, 2 representative data are displayed with Ctl (n=4), and Prop (n=5). Data are expressed as mean 6
SD. *** denotes P,0.001, ** denotes P,0.01, and * denotes P,0.05 vs. Ctl with unpaired t-test.
doi:10.1371/journal.pone.0016648.g001
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conditions does not induce pathological somato-dendritic reloca-
lization of tau.
Tau Hyperphosphorylation Under Normothermic
Conditions Persists at the AT8 Phosphoepitope in the
Mouse Hippocampus Following Recovery From
Anesthesia
We next determined whether the increase in hippocampal tau
phosphorylation under normothermic conditions persists following
recovery from propofol anesthesia. Thirty minutes following the
administration of propofol, hippocampal tau phosphorylation at
the AT8 epitope significantly increased to 282654% of control
(Fig. 3A1), confirming our previous results. However, in the group
sacrificed 2 h following propofol, despite the recovery of the
righting reflex in all of these mice, hippocampal tau hyperpho-
sphorylation persisted at the AT8 epitope and was 195631% of
control (Fig. 3A1). Interestingly, there were significant increases in
hippocampal tau phosphorylated at the PHF-1 (14866%) and
CP13 (153626%) phosphoepitopes 30 min following propofol
(Fig. 3A2, A3); however, 2 h following anesthesia PHF-1 and
Figure 2. Regional anatomical localization of tau phosphorylation following 30 min of anesthesia with propofol. Fluorescence
photomicrographs of hippocampal sagittal sections are shown with AT8 (Green, A,B,C), Total Tau (Red, D,E,F), or merged with DAPI (Green-Red-Blue,
G,H,I), for the following conditions: Control (Intralipid, A,D,G), Hypothermia (B,E,H), and Normothermia (C,F,G). All images were taken at 5x magnification.
doi:10.1371/journal.pone.0016648.g002
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the increase in hippocampal tau phosphorylation at 30 min was
greatest at AT8 when compared to the increases observed at PHF-
1 and CP13. There were no observed changes in hippocampal
total tau levels throughout the study (Fig. 3A4). Normothermia
was maintained and rectal temperatures were similar in all 3
groups: Control =37.360.2uC, Prop 30 min =36.860.2uC, and
Prop 2 h =37.160.4uC.
Because of this persistence of tau hyperphosphorylation at the
AT8 phosphoepitope, we performed a subsequent set of
experiments in C57BL/6 mice to determine whether tau
phosphorylation at this specific phosphoepitope returns to control
levels 6 h following propofol administration. Normothermia was
maintained throughout and rectal temperatures were similar in all
3 groups: Control =37.160.3uC, Prop 0.5 h =36.960.2uC, and
Prop 6 h =37.060.3uC. As previously observed, 30 min (Prop
0.5 h, n=5) following propofol, tau phosphorylation at AT8,
PHF-1, and CP13 significantly increased compared to control
(Ctrl, n=4); however, by 6 h (Prop 6 h, n=5) following propofol,
tau phosphorylation had returned to control levels at all 3
phosphoepitopes (Fig. 3B1, B2, B3). There was a slight increase of
total tau after 6 h (11167%). Of note, in this group of mice, the
increase in tau phosphorylation at AT8 was again greater than
that observed at PHF-1 and CP13.
Hence, under normothermic conditions, propofol produces an
immediate increase in tau phosphorylation at the AT8, PHF-1,
and CP13 phosphoepitopes; however, at the AT8 phosphoepitope
tau hyperphosphorylation persists 2 h following anesthesia but
recovers 6 h following propofol treatment. Furthermore, the
greater degree and longer duration of hyperphosphorylation at
AT8, when compared to PHF-1 and CP13, suggests that this
phosphoepitope is more susceptible to the hyperphosphorylation
effects of propofol.
Propofol Induces Transient Tau Hyperphosphorylation in
the Mouse Cortex Under Normothermic Conditions
To determine whether regional brain differences in tau
phosphorylation exist, we also examined levels of tau phosphor-
ylation at the AT8, PHF-1, pS262, MC6 and pS422 phosphoe-
pitopes in cortical tissue harvested 30 min (0.5 h, n=6) or 2 h
(2 h, n=7) following the administration of propofol or intralipid
(Ctrl, n=6). In the cortex, tau phosphorylation at the AT8
phosphoepitope increased to 154628% of control 30 min and to
144629% of control 2 h following propofol administration
(Fig. 4.1), confirming the results from the hippocampal tissues.
Moreover, a significant increase in tau phosphorylation was
observed in the cortex at the PHF-1 (141630%), pS262
(2256112%), MC6 (143642%), and pS422 (130621%) epitopes
30 min but not 2 h after propofol treatment (Fig. 4.2 to 4.5).
Propofol produced no significant change in total tau (Fig. 4.6) or b-
tubulin (data not shown) in the cortex. Again, these data
demonstrate that tau hyperphosphorylation following propofol is
Figure 3. Tau phosphorylation in mouse hippocampal tissue 0.5 h and 2 h (A), or 0.5 h and 6 h (B) following the administration of
propofol under normothermic conditions. Hippocampal protein extracts were separated by SDS-PAGE and levels of tau phosphorylation were
determined using antibodies directed at the AT8 (A1, B1), PHF-1 (A2, B2), and CP13 (A3, B3) phosphoepitopes, or Total Tau (A4, B4). Relative
immunoreactive band intensities are expressed as a percent of control (Ctl; intralipid) and are displayed for each phosphoepitope and total tau. For
each condition, 1 representative datum is displayed with Ctl (n=4), 0.5 h (n=5), 2 h (n=5), or 6 h (n=5). Data are expressed as mean 6 SD. *, ** and
*** denote P,0.05, P,0.01 and P,0.001 vs. ctl, respectively; ANOVA with Newman-Keuls post hoc test.
doi:10.1371/journal.pone.0016648.g003
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susceptible to propofol-induced hyperphosphorylation.
Impact of Propofol on Tau Kinases and Phosphatases
As our results demonstrate that tau hyperphosphorylation
following propofol anesthesia occurs under normothermic condi-
tions, we next examined the activation state of specific tau kinases
as well as the protein expression levels of phosphatases commonly
involved in the regulation of tau phoshorylation. Among the
kinases capable of phosphorylating tau, glycogen synthase kinase-
3b (GSK-3b), cyclin-dependent kinase 5 (cdk5) and p35 (a specific
activator of cdk5), mitogen-activated protein kinase/extracellular
signal-regulated kinase (MAPK/ERK), and c-Jun N-terminal
kinase (JNK) are considered to be major physiological and
pathological tau kinases [21,22,23]. AKT/PKB (Protein Kinase
B) can enhance tau phosphorylation directly [24] or indirectly by
modulating the inhibitory phosphorylation of GSK-3b at Ser
9
[25]. CaMKII is also thought to have a major role in regulating
the phosphorylation of tau at epitopes that modulate the binding
of tau to microtubules [26]. We explored the activation patterns of
these six kinases with specific antibodies in the same cortical tissues
obtained from mice that received propofol 250 mg/kg i.p. and
were subsequently sacrificed 30 min or 2 h following drug
administration. Thirty minutes following propofol there was
significant increase in p-GSK-3b (Ser 9) levels (Fig. 5.1), a
significant decrease in p-ERK (Fig. 5.3), and a slight decrease in
total AKT levels (Fig. 5.10), but all the other kinases examined did
not change (Fig. 5). Two hours following propofol the decrease in
p-ERK persisted while p-CaMKII was significantly increased
(Fig. 5.7); there were also significant increases in CDK5 and P35
levels (Fig. 5.11 and 5.12). However, there was no correlative
kinase activation that could explain the tau hyperphosphorylation
observed 30 min after treatment.
We therefore examined next the levels of tau protein
phosphatases (PP) catalytic subunits 30 min and 2 h after propofol
administration. Tau can be dephosphorylated by PP1, PP2A, and
PP2B, but PP2A shows a much stronger capacity to dephosphor-
ylate tau [27,28]. The only detectable change was a significant
decrease in PP2A-C 30 min after treatment (Fig. 6.3; 7662%),
suggesting a decrease in PP2A activity, which was confirmed with
an immunoprecipitation assay (Fig. 6.4; 7769%).
Propofol Induces Transient Tau Hyperphosphorylation in
SH-SY5Y cells
We next determined the effect of propofol on tau phosphory-
lation in vitro using SH-SY5Y human neuroblastoma cells stably
transfected to overexpress human tau (Tau-SH-SY5Y cells). These
studies were performed to determine whether propofol-induced
tau hyperphosphorylation is the result of a direct pharmacologic
effect and not the consequence of an anesthetic-induced
physiologic change. First, as a positive control, we examined the
degree of tau phosphorylation in the cells at the AT8 epitope
following 1 h incubation at 37uC (control, n=4) or 30uC (n=3).
Following a 1 h incubation of the Tau-SH-SY5Y cells at 30uC, tau
phosphorylation increased to 245618% of the control (37uC)
group (Fig. 7A1), confirming that these transfected cells respond
Figure 4. Tau phosphorylation in mouse cortical tissue 30 min and 2 h following the administration of propofol under
normothermic conditions. Cortical protein extracts were separated by SDS-PAGE and levels of tau phosphorylation were determined using
antibodies directed at the AT8 (1), PHF-1 (2), pS262 (3), MC6 (4), and pS422 (5) phophoepitopes, or Total Tau (6). Relative immunoreactive band
intensities are expressed as a percent of control (Ctl; intralipid) and are displayed for each phosphoepitope and total tau. For each condition, 1
representative datum is displayed with Ctl (n=6), 0.5 h (n=6), and 2 h (n=7). Data are expressed as mean 6 SD. *, and ** and denote P,0.05, and
P,0.01 vs. Ctl, respectively; ANOVA with Newman-Keuls post hoc test.
doi:10.1371/journal.pone.0016648.g004
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to increase tau phosphorylation. Total tau was slightly decreased
(Fig. 7A2; 8562%). In the propofol experiments, when compared
to control (n=3), 1 h following exposure to propofol 3 ug/ml
(n=5), a physiologic dose of propofol, tau phosphorylation at AT8
increased significantly in the Tau-SH-SY5Y cells to 215635% of
control (Fig. 7B1). Significant increases in phosphorylated tau at
CP13 (170617%; Fig. 7B2) and PHF-1 (12569%; Fig. 7B3) were
also observed with the 3 ug/ml concentration. No significant
change in total tau (Fig. 7B4) or b-actin (data not shown) were
observed among the 3 treatment groups. These results demon-
strate that propofol can induce direct tau hyperphosphorylation in
neuronal cells, and suggest that, as propofol can cross the blood-
brain barrier [29], the outcome observed in mice is probably due
to a direct pharmacologic effect on neurons.
Discussion
The findings of the present study are novel and demonstrate
that a common clinically used intravenous anesthetic, propofol,
can increase tau phosphorylation in the mouse hippocampus and
cortex, not only as a consequence of anesthesia-induced
hypothermia, but also due to a direct effect of the drug itself.
Furthermore, in the hippocampus, tau hyperphosphorylation at
the AT8 phosphoepitope persists for at least 2 h following propofol
administration before returning to control levels 6 h later, thus
demonstrating that direct tau hyperphosphorylation by propofol
can persist even following recovery from the sedative-hypnotic
effects of the drug. The observation that normothermic hyperpho-
sphorylation following anesthesia occurred within a clinically
relevant time frame, 30 min and 2 h following exposure, is also
novel.
We previously observed that the hyperphosphorylation of tau
following intravenous and inhalational anesthetics primarily
involves the inhibition of PP2A by anesthetic-induced hypother-
mia [15]. Our data clearly supports this previous finding as
propofol-induced hypothermia produced tau hyperphosphoryla-
tion that was significantly greater than that observed under
normothermic conditions. However, in contrast to our previous
study, we observed a direct effect of an intravenous anesthetic on
Figure 5. Effect of propofol on tau kinases in mouse cortical tissue 0.5 h and 2 h following the administration of propofol under
normothermic conditions. Cortical protein extracts were separated by SDS-PAGE and levels of kinases were determined using antibodies directed
at activated or total kinases as follow: (1) GSK-3b phospho-S9, (2) total GSK-3 (a and b), (3) phospho-ERK, (4) total ERK, (5) phospho-JNK, (6) total JNK,
(7) phospho-CaMKII, (8) total CaMKII, (9) phospho-AKT, (10) total AKT, (11) CDK5, and (12) P35. Relative immunoreactive band intensities are expressed
as a percent of control (Ctl; intralipid) and are displayed for each epitope. For each condition, 1 representative datum is displayed with Ctl (n=6),
0.5 h (n=6), and 2 h (n=7). Data are expressed as mean 6 SD. *, ** and *** denote P,0.05, P,0.01 and P,0.001 vs. ctl, respectively; ANOVA with
Newman-Keuls post hoc test.
doi:10.1371/journal.pone.0016648.g005
Propofol Increases Tau Phosphorylation
PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e16648tau phosphorylation in the absence of hypothermia. One possible
reason for this observed difference includes the fact that in the
current study, we examined propofol, a phenol-based derivative
that is structurally and chemically unrelated to the intravenous
anesthetics we previously examined, namely pentobarbital and
choral hydrate. Furthermore, in the aforementioned study, the
normothermic animals were allowed to initially become hypo-
thermic followed by a period of ‘‘rescue normothermia’’.
However, in the present study, normothermia was maintained
throughout the administration of anesthesia, thus avoiding any
temperature-related changes in tau-related kinase or phosphatase
activity. Temperature fluctuations can affect the relative balance of
tau-related kinase and phosphatase activity [30]; hence, the
maintenance of normothermia throughout the study virtually
eliminated the possibility that hypothermia-induced inhibition or
activation of these enzymes would be a factor during the
determination of the direct effects of propofol on tau phosphor-
ylation.
More recent studies have observed that either ether or sodium
pentobarbital anesthesia can directly lead to hyperphosphorylated
tau both 30 sec and 5 min following treatment, as no evidence of
hypothermia was observed by these investigators at either of these
time points [18]. The present study expands on these findings by
demonstrating the effects of a general anesthetic dose of a more
clinically-utilized anesthetic at clinically relevant time intervals:
30 min and 2 h following anesthesia. Similar to Run et al., we
observed that the degree of hyperphosphorylation observed
following anesthesia varies as a function of the specific phosphoe-
pitope. Specifically, we observed the greatest increase in tau
phosphorylation following 30 min of propofol treatment at the
AT8 phosphoepitope, and to a lesser extent at CP13, PHF-1,
pS262, MC6, and pS422, in the hippocampus or the cortex.
Figure 6. Effect of propofol on tau phosphatases in mouse
cortical tissue 0.5 h and 2 h following the administration of
propofol under normothermic conditions. Cortical protein ex-
tracts were separated by SDS-PAGE and levels of phosphatases were
determined using antibodies directed at the following proteins: (1) PP1
catalytic subunit, (2) PP2B catalytic subunit, and (3) PP2A catalytic
subunit. Relative immunoreactive band intensities are expressed as a
percent of control (Ctl; intralipid) and are displayed for each epitope.
For each condition, 1 representative datum is displayed. (4) PP2A
activity was measured with the PP2A Immunoprecipitation Phosphatase
BioAssay Kit from US Biological and values expressed as percentage of
control. All data are expressed as mean 6 SD. * and ** denote P,0.05
and P,0.01 vs. ctl, respectively; Ctl (n=6), 0.5 h (n=6), and 2 h (n=7);
ANOVA with Newman-Keuls post hoc test.
doi:10.1371/journal.pone.0016648.g006
Figure 7. Effect of propofol on tau phosphorylation in Tau-SH-
SY5Y cells. Cells were harvested after 1 h incubation at 37uC (n=4) or
30uC (n=3) in the absence of propofol (A), or following 1 h exposure to
10% intralipid in DMEM (Ctl, n=3) or propofol (Prop, n=5) at 3 mg/ml
(16.8 mM), both at 37uC( B). Cell lysate protein extracts were separated
by SDS-PAGE and the level of tau phosphorylation was determined
using antibodies directed at the AT8 (A1, B1), CP13 (B2), or PHF-1 (B3)
phosphoepitopes, or total tau (A2, B4). Relative immunoreactive band
intensities are expressed as a percent of control and are displayed for
each phosphoepitope and total tau. Tau phosphoepitopes are
normalized on total tau. For each condition, 2 representative data are
displayed. Data are expressed as mean 6 SD, with *, **, and ***
denoting P,0.05, P,0.01 and P,0.001 vs. ctl, respectively with
unpaired t-test.
doi:10.1371/journal.pone.0016648.g007
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(pSer
202/pThr
205) after 2 h in both brain regions, also suggests
that propofol has a greater capacity to produce hyperpho-
sphorylation at certain phosphoepitopes.
As tau phosphorylation is regulated by the activity of several
protein kinases [31,32,33] and protein phosphatases [34,35,36],
we examined the expression and/or activation of several of these
enzymes. Thirty min after propofol treatment, there was no
increase in kinases activation, but the decrease in PP2A-C
expression and PP2A activity, along with the increase of
phospho-GSK-3b (Ser9) levels strongly suggests that propofol
may be producing its effect on tau phosphorylation (at AT8, CP13,
MC6, PHF-1, pS262, and pS422) not primarily by the activation
of kinases, but rather through an inhibition of PP2A activity.
Indeed, increased levels phospho-tau at all epitopes examined,
along with increased phospho-GSK-3b (Ser9) have been consis-
tently observed during inhibition of phosphatases, either by
okadaic acid in neuronal cultures [36] or by hypothermia in mice
[15,30]. On the other hand, a significant decrease in p-ERK, and
increases in levels of p-CaMKII, cdk5 and its activator p35 were
also observed at 2 h. Among the phospho-tau epitopes examined
here, ERK is known to phosphorylate AT8, CP13, MC6, PHF-1,
and pS422; cdk5 can phosphorylate AT8, CP13, MC6, and PHF-
1; CaMKII is more specific to pS262 (for a table recapitulating the
kinases and their in vitro target epitopes on tau, see [22]). Thus, the
increase in CaMKII activation was not reflected by an increase in
pS262 levels, and p-ERK was diminished, which suggest that they
are not directly implicated in the persistent phosphorylation of
AT8 at 2 h. It should be noted that it is not the first time that we
observe increased CaMKII activation not correlating with
increased tau phosphorylation in vivo; for example, 10 days of
diabetes induced by streptozotocin resulted in more than 1000%
increase in p-CaMKII but no detectable phosphorylation at either
pS262 or pS356, two sites demonstrated to be phosphorylated by
CaMKII in vitro [48]. The increase in cdk5 and p35 might have
explained the persistent phosphorylation at AT8 at 2 h, but other
epitopes known to be phosphorylated by cdk5, such as MC6,
CP13 and PHF-1 were not increased, which suggest that cdk5 is
not directly responsible for the persistent AT8 phosphorylation.
Overall, our results suggest that the mechanism of tau phosphor-
ylation after propofol treatment is biphasic, with an inhibition of
PP2A resulting in tau hyperphosphorylation at multiple epitopes
after 30 min, followed by the persistence of AT8 phosphorylation
at 2 h. This persistence might be due to residual phosphorylation
or the activation of an unknown kinase specific for the AT8 site.
Although it would be premature to extrapolate these preclinical
findings to the clinical sphere at this juncture, the observation that
propofol has direct effects on tau phosphorylation should not be
underestimated. This is especially true given the fact that unlike
anesthetics previously studied in the context of their capacity to
produce tau hyperphosphorylation such as isoflurane, ether,
choral hydrate, and sodium pentobarbital [15,17,18], propofol is
an anesthetic that is administered not solely intraoperatively for a
few hours, but also for days as the drug is commonly used for post-
operative sedation in critical care settings such as intensive care
units. Indeed, Wunsch et al. recently demonstrated that propofol is
currently the most common form of intravenous anesthetic utilized
for sedation purposes in U.S. intensive care units [19]. Hence, our
current finding of propofol-induced tau hyperphosphorylation and
its persistence at select phosphoepitopes following a short period of
general anesthesia, makes it plausible that this state of abnormal
phosphorylation may also persist in the setting of prolonged
administration. Given that post-operative cognitive impairment is
commonly observed following intensive care [37], the observation
that an anesthetic commonly used for ICU sedation is associated
with a direct increase in tau phosphorylation suggests that the
contribution of this hyperphosphorylation to the development of
tau neurofibrillary pathology and neurocognitive impairment
warrants further investigation.
Materials and Methods
Animals
The experimental protocol was approved by the Columbia
University Animal Care and Use Committee and, in accordance
with National Institutes of Health (NIH) guidelines, adequate
measures were taken to minimize pain and discomfort. Seven to
nine-week-old C57BL/6 male mice were purchased from a
commercial vendor (Taconic, Germantown, NY) and utilized in
this study. The mice were housed in a temperature-controlled
room at 22uC and were kept on a 12 h/12 h light/dark cycle. All
animals had access to food and water ad libitum, and they
underwent an acclimatization period for a minimum of 24 h
before being used in the experiments.
Anesthesia exposure
On the day of the study, a 25 mg/ml solution of propofol (MP
Biomedicals, Solon, OH) in intralipid (20% emulsion) was freshly
prepared. In all of the experiments, the mice were exposed to
either propofol (MP Biomedicals, Solon, OH) 250 mg/kg or an
equivalent volume of intralipid (vehicle control for propofol, Sigma
RBI, St. Louis, MO) via intraperitoneal (i.p.) injection. The
control mice were returned to their home cage at room
temperature after injection. All of the anesthetized mice were
initially anesthetized in their home cage, and, once sedated, they
were transferred to a ThermocareH ICS therapy warmer unit
(Thermocare, Incline Village, NV) either set to maintain a mouse
body temperature of ,37uC or with the heating element turned
off, the latter setting used to achieve propofol-induced hypother-
mia. Rectal temperature was monitored using an electronic
thermometer probe (Thermalert TH-5, Physitemp, Clifton, NJ).
Preparation of Mouse Brain Protein Extracts
Following propofol or intralipid exposure, the mice were killed
by cervical dislocation either 30 min, 2 h, or 6 h following drug or
vehicle administration, then the brain was immediately removed
and dissected in ice-cold Tris-EDTA buffer (Tris HCl 100 mM,
1 mM EDTA, pH 7.4). The hippocampal and cortical tissues were
immediately frozen in liquid nitrogen and stored at 280uC.
Protein extracts were prepared by mechanically homogenizing the
hippocampal and cortical tissues in 5x vol/w RIPA buffer
containing 50 mM Tris-HCl (Sigma-Aldrich, St. Louis, MO),
pH 7.4, 1 mM ethylenediaminetetraacetic acid (EDTA), 150 mM
NaCl, 0.1% SDS (Sigma), 0.5% sodium deoxycholate, 1% NP-40
(Sigma), phosphatase inhibitors (Cocktail 1 and 2, Sigma, 1:100
dilution), and protease inhibitors (Cocktail set III, Calbiochem,
San Diego, CA, 1:200 dilution). The samples were incubated on
ice for 30 min, sonicated for 30 s in pulse mode, and then
centrifuged at 11,000 g for 10 min at 4uC. Total protein content
was determined in the supernatant using the bicinchoninate (BCA)
method [38].
Cell Culture Studies and Cell Lysate Protein Extract
Preparation
Propofol-induced tau phosphorylation was also examined using
SH-SY5Y human neuroblastoma cells stably transfected to
constitutively express human tau with 3 microtubule binding
domains [39,40,41]. These Tau-SH-SY5Y cells were a kind gift of
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grown initially in 25-cm
2 flasks containing Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal calf serum, 3 mM L-
glutamine, 1 mM nonessential amino acids as well as 50 units/ml
penicillin/streptomycin (DMEM and cell culture additives were
purchased from Invitrogen, Carlsbad, CA), and were maintained
in a 5% humidified incubator at 37uC. In preparation for
anesthetic or vehicle exposure, the cells were transferred into 6-
well plates and used at approximately 70% confluency.
On the day of the experiment, the growth medium was removed
by aspiration, and each well was washed 2 times with 1 ml of fresh
DMEM containing no additives. Immediately following the wash,
each well received either 1.5 ml of Propofol (3 mg/ml) in 10%
intralipid in DMEM or 10% intralipid in DMEM (vehicle). The
concentration of propofol utilized was prepared using the
commercial formulation of propofol (DiprivanH, AstraZeneca
Pharmaceuticals, Wimington, DE) and based on a concentration
previously utilized in cell culture studies [42]. This 3 mg/ml
concentration of propofol (16.8 mM) is within the concentration
range of that measured in human plasma following the clinical
administration of this anesthetic [29]. The 6-well plates were
incubated with propofol or vehicle for 1 h at 37uC. Following the
1 h exposure, the propofol or vehicle solutions were removed by
aspiration, and each well was rinsed 2 times with 1 ml of ice-cold
phosphate buffered saline. Furthermore, to confirm that the Tau-
SH-SY5Y cells responded appropriately to treatments known to
alter the tau phosphorylation state, we performed an additional set
of experiments in these cells in which we incubated the cells for 1 h
in normothermic (37uC) or hypothermic (30uC) conditions, the
latter condition being known to increase tau phosphorylation
[15,30]. At the end of each treatment period, the cells were
harvested by scraping in 200 mL of ice-cold RIPA buffer
containing phosphatase- (1:100, Sigma-Aldrich, St. Louis, MO)
and protease (1:200, EMD Chemicals, Gibbstown, NJ) inhibitors,
and the samples were stored at 280uC until they were utilized in
the immunoblotting analyses.
In preparation for SDS-PAGE and Western blot analysis, the
cells were lysed on ice for 30 min and then sonicated on ice for
20 s in pulse mode at 30% power output. The lysate was then
centrifuged at 1000 g for 10 min at 4uC, and the supernatant
collected and analyzed for protein content using the bicinchoni-
nate (BCA) method [38].
SDS-PAGE and Western Blot Analysis
The expression of phosphorylated tau, total tau as well as the
tau kinases and phosphatases was determined using SDS-
polyacrylamide gel electrophoresis (PAGE) coupled with Western
blot analysis. Brain homogenate or cell lysate aliquots containing
30 mg protein were separated on a SDS-10% polyacrylamide gel
and then transferred onto nitrocellulose membranes (Amersham
Biosciences, Pittsburgh, PA). Non-specific binding sites were
blocked with 5% nonfat dry milk in Tris-buffered saline containing
0.1% Tween 20 for 1 h at room temperature and then were
incubated overnight at 4uC with antibodies directed against either
total tau, phosphorylated tau, a specific tau kinase or phosphatase.
The following day the membranes were washed 3 times and then
incubated for 1 h at room temperature with a horseradish
peroxidase-linked secondary anti-mouse antibody (Cell Signaling
Technology, Boston, MA, 1:2500 dilution), and the immunoreac-
tive band signal intensity was visualized by enhanced chemilumi-
nescence (ECL Plus, GE Healthcare Biosciences, Piscataway, NJ).
The immunoreactive bands were scanned using Fujifilm LAS
4000 imaging system (Fujifilm USA, Valhalla, NY) and densito-
metric analysis was performed on these scans with Image GaugeH
analysis software (Fujifilm USA, Valhalla, NY).
Detection of Total and Phosphorylated Tau
Antibodies were utilized in the study that were directed at tau
phosphorylated at the following epitopes: AT8 (pSer
202/pThr
205
[43], 1:250 dilution, Pierce Biotechnology), PHF-1 (pSer
396/Ser
404
[44], 1:1000), MC6 (pSer
235 [45], 1:1000), CP13 (pSer
202 [46],
1:1000), pS262 (pSer
262, 1:1000; Invitrogen, Camarillo, CA,
USA), and pS422 (pSer
422; 1:1000; Invitrogen). Total tau was
detected using one of the following antibodies that detects all 6 six
isoforms of tau: Tau46 (monoclonal, 1:2500, Cell Signaling
Technology, Danvers, MA), TG5 (monoclonal [47], 1:1000), or
Tau A0024 (polyclonal, 1:10,000, Dako Cytomation). The PHF-1,
CP13, MC6, and TG5 antibodies were a generous gift from Dr.
Peter Davies (Albert Einstein University, New York, NY).
Detection of Kinases and Phosphatases
Changes in tau kinases were examined using GSK-3b (1:1000,
BD Transduction Lab, Franklin Lakes, NJ), and the following
antibodies purchased from New England Biolabs, Pickering,
Ontario, Canada: phospho-GSK-3b (Ser
9, 1:1000), SAPK/JNK
(1:1000,), phospho-SAPK-JNK (Thr
183/Tyr
185, 1:1000,), p44/42
MAPK (Erk 1/2, 1:1000), phospho p44/42 MAPK (Erk 1/2,
Thr
202/Tyr
204, 1:1000). Changes in tau phosphatases were
examined using PP2A-C subunit (Cell Signaling, 1:1000), pan-
calcineurin A (PP2B, Cell Signaling, 1:1000), PP1 catalytic subunit
(E-9, Santa Cruz, 1:1000).
PP2A activity was assayed with the PP2A Immunoprecipitation
Phosphatase BioAssay Kit from US Biological (Swampscott, MA,
USA), according to the manufacturer instructions, and as
described previously by us [48]. Briefly, brain hemispheres were
homogenized in 40 x volume/weight of 20 mM imidazole-HCl
pH 7.0, 2 mM EDTA, 2 mM EGTA, 1 mM PMSF, 10 ml/ml of
Protease Inhibitor Cocktail P8340 (Sigma-Aldrich), and centri-
fuged at 2000 g for 5 min at 4uC. PP2A catalytic subunit was
immunoprecipitated from the supernatant with a monoclonal
antibody and protein A agarose for 2 hours at 4uC. The activity of
the immunoprecipitated PP2A was assessed by the release of
phosphate from a chemically synthesized phosphopeptide over a
period of 10 min at 30uC. The amount of phosphate released was
measured by the absorbance of the molybdate-malachite green-
phosphate complex at 630 nm.
Statistical Analysis
Group comparisons of immunoblot relative band intensities or
PP2A assay results were performed using a one-way analysis of
variance (ANOVA) with Newman-Keuls Multiple Comparison
post hoc test applied when appropriate or by means of an unpaired
t-test. The data were tested for normality using the Kolmogrov-
Smirnov test. Statistical calculations were performed using Prism
4H software (GraphPad Software, Inc., San Diego, CA), and all
data are reported as mean 6 SD with a value of P,0.05
considered statistically significant.
Immunofluorescence
Tissue fixation was done according to the ‘‘cold Bouin’s
method’’ developed in our laboratory [30]. Briefly, animals were
decapitated, the brain was quickly removed and immersed in ice-
cold Bouin’s solution (saturated picric acid, formalin, acetic acid at
15:5:1) for 24 hr and embedded in paraffin blocks. Eight to ten mm
thick sections were processed for immunofluorescent analyses.
Deparaffinized and hydrated sections were incubated in 7%
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1 hr. The specimens were incubated with the primary antibodies
diluted in PBS 0.1M containing 0.04% triton overnight at 4uC.
The following antibodies were used: AT8 (monoclonal, 1:200
dilution, Pierce Biotechnology, Rockford, IL) and Tau A0024
(polyclonal, 1:1000, Dako Cytomation, Carpinteria, CA, USA).
Bound antibodies were visualized with Alexa Fluor 488 conjugated
anti-mouse IgG (1:500 dilution) or Alexa Fluor 568 conjugated
anti-rabbit IgG (1:1000 dilution) (Molecular Probes, Eugene, OR).
Slices were mounted with a Vectashield Hard Set Mounting
Medium containing DAPI (Vector Laboratories, Inc, Burlingame,
CA). Immunolabeled tissues were observed under a Carl Zeiss
Axio Imager M2 (Zeiss, Jena, Germany) microscope equipped
with an Axiocam MRm (Zeiss, Jena, Germany) and the Axiovision
Rel.4.8 software.
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